This book is a cutting-edge resource that provides clinicians with the up-to-date practical knowledge required in order to manage SCC patients optimally. It summarizes newly available information relating to the definition of high-risk SCC, its pathophysiologic underpinnings, and its management. New prognostic information and staging systems are summarized that enable high-risk tumors to be defined more precisely than ever before. Many helpful tips are provided on the practical management of challenging cases, including multiple tumors/field cancerization, high-risk tumors, nodal metastases, and unresectable disease. The authors are all acknowledged experts in the emerging field of high-risk and advanced SCC.​

Non-melanoma skin cancer is a global public health issue. With an ever-increasing, and ageing, world population coupled with increasing numbers of immunosuppressed individuals the number of patients continues to rise. The head and neck is overwhelmingly the most frequent location for the development of a non-melanoma skin cancer and as such challenges the clinician with its complex anatomy. The importance of maintaining the aesthetics of the face and the function of the anatomy cannot be overstated, yet ultimately it is always the aim of curing a patient with the minimum of morbidity that clinicians strive for. However, the spectrum of presentations and subsequent management varies widely, ranging from patients with the ubiquitous low-risk mid-face basal cell carcinoma to those diagnosed with relatively uncommon but potentially life-threatening high-risk squamous cell carcinomas (e.g. involving metastatic lymph nodes or with perineural invasion present) and Merkel cell carcinomas.

Mohs Micrographic Surgery, an advanced treatment procedure for skin cancer, offers the highest potential for recovery--even if the skin cancer has been previously treated. This procedure is a state-of-the-art treatment in which the physician serves as surgeon, pathologist, and reconstructive surgeon. It relies on the accuracy of a microscope to trace and ensure removal of skin cancer down to its roots. This procedure allows dermatologists trained in Mohs Surgery to see beyond the visible disease and to precisely identify and remove the entire tumor, leaving healthy tissue unharmed. This procedure is most often used in treating two of the most common forms of skin cancer: basal cell carcinoma and squamous cell carcinoma. The cure rate for Mohs Micrographic Surgery is the highest of all treatments for skin cancer--up to 99 percent even if other forms of treatment have failed. This procedure, the most exact and precise method of tumor removal, minimizes the chance of regrowth and lessens the potential for scarring or disfigurement

This book offers a selection of pertinent patient case-presentations in the field of rhinology, anterior skull base and facial plastics surgery. It further explores the evidence-based management of simple to complex clinical presentations. Each chapter start with the diagnosis and progresses from medical or surgical treatment to the post-operative follow up of the presented clinical condition. The various case reports are concise; however, sufficiently comprehensive and cover conditions from emergencies in adult and paediatric rhinology, to elective care, sino-nasal and anterior skull base neoplasms systemic diseases affecting the nose and paranasal sinuses, and underpinned by illustrations, imaging, and intra-operative photographs to emphasize the clinical approach. Rhinology and Anterior Skull Base Surgery - A Case-based Approach is a highly informative and carefully presented book, providing insights for exam candidates, trainees, general practitioners, rhinologists and otolaryngologists with an interest in anterior skull base, facial plastics and rhinology.

This book addresses the most relevant aspects of radiation oncology in terms of technical integrity, dose parameters, machine and software specifications, as well as regulatory requirements. Radiation oncology is a unique field that combines physics and biology. As a result, it has not only a clinical aspect, but also a physics aspect and biology aspect, all three of which are inter-related and critical to optimal radiation treatment planning. In addition, radiation oncology involves a host of machines/software. One needs to have a firm command of these machines and their specifications to deliver comprehensive treatment. However, this information is not readily available, which poses serious challenges for students learning the planning aspect of radiation therapy. In response, this book compiles these relevant aspects in a single source. Radiation oncology is a dynamic field, and is continuously evolving. However, tracking down the latest findings is both difficult and time-consuming. Consequently, the book also comprehensively covers the most important trials. Offering an essential ready reference work, it represents a value asset for all radiation oncology practitioners, trainees and students.

This open access book offers an essential overview of brain, head and neck, and spine imaging. Over the last few years, there have been considerable advances in this area, driven by both clinical and technological developments. Written by leading international experts and teachers, the chapters are disease-oriented and cover all relevant imaging modalities, with a focus on magnetic resonance imaging and computed tomography. The book also includes a synopsis of pediatric imaging. IDKD books are rewritten (not merely updated) every four years, which means they offer a comprehensive review of the state-of-the-art in imaging. The book is clearly structured and features learning objectives, abstracts, subheadings, tables and take-home points, supported by design elements to help readers navigate the text. It will particularly appeal to general radiologists, radiology residents, and interventional radiologists who want to update their diagnostic expertise, as well as clinicians from other specialties who are interested in imaging for their patient care.

Human skin cancers, the most common type of tumors, represent a significant health burden. The deadliest is unquestionably melanoma. Half of melanomas have an activating mutation in the BRAF gene, prompting development of novel drugs, vemurafenib and dabrafenib, specifically targeting mutated BRAF. Trametinib and cobimetinib, which block MEK, a BRAF effector protein, have been used in combination with BRAF inhibitors. A promising new melanoma treatment is immunotherapy, approach that boosts patient's own immune system to attack cancer. Pembrolizumab and nivolumab inhibit PD-1, whereas Ipilimumab targets CTLA-4, another immunity check point, to boost the immune response. Here we focus on pathways, mechanisms, targets and treatments of human skin cancers, with particular emphasis on the new developments in the research on melanomas.